DailyIQ
Last updatedjust now

PODD·Insulet Corporation

$137.32
-0.81 (-0.59%)
High
$139.75
Open
$139.72
Market Cap
9.77B
52W High
$361.24
Low
$137.21
P. Close
$137.32
P/E
26.01
52W Low
$126.40
Fwd P/E
17.89
DailyIQ Est.
$172.08
Inst. Ownership
51.5%
Short Interest
7.60%
Days to Cover
3.9
NewEarnings release, scored · filed Aug 5, 2026New outlook issued · tone -5.1 vs prior release · 27 lines scoredSee the breakdown
Technical Score (1D)
18
BEARISH
News Sentiment
45
MIXED
PODD is a momentum laggard on the 1D chart: a Technical Score of 18 with declining momentum and weak trend strength. The score ranks stocks against each other, so a reading this low says Insulet Corporation has been one of the weaker performers in the universe, not that it is oversold. Sentiment at 45 is aligned with that weakness. $140.45 is the level a recovery would need to reclaim, and $126.95 is the next downside reference below $129.65. A bottom momentum rank reflects the prior year of trading, so it changes gradually even when the stock has a strong week. For near-term direction, price levels give the earlier read: a close back above $140.45 on real volume would be the first sign of repair, while a break of $129.65 keeps the bearish trend in charge.
LOW TARGET
$143 +4.1%
2 analysts
MEAN TARGET
$167 +21.7%
15 analysts
HIGH TARGET
$215 +56.6%
18 analysts
PRICE RANGE
$143.00 - $215.00
SB / B / H / S / SS
9/11/13/1/1
DAILYIQ EST.
$172.08 (+25.3%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NMS
Country
United States
Symbol
PODD
Description
Insulet Corporation is a medical device company specializing in insulin delivery systems for individuals managing insulin-dependent diabetes. Its core offering is the Omnipod platform, featuring the Omnipod 5, an automated insulin delivery system that integrates with continuous glucose monitors for real-time glucose monitoring and insulin adjustments. The company also offers the Omnipod DASH system, a user-friendly insulin management system controlled via a smartphone-like device. Furthermore, Insulet manufactures pods for Amgen's Neulasta Onpro kit, a delivery system designed to mitigate infection risks for chemotherapy patients. Insulet distributes its products through pharmacies and independent distributors, providing a comprehensive solution for insulin delivery.
Bought (1Y)
7,340 shares
$1.1M
Sold (1Y)
3,955 shares
$556K
Pease FlaviaEVP & CFO
Tax Withholding1,882 shares2026-10-01
Huffines Robert Luther-
Award/Grant178 shares2026-09-30
MAZELSKY JONATHAN JAY-
Award/Grant141 shares2026-09-30
McEvoy AshleyPresident and CEO
Buy1,100 shares2026-08-21
Davis Lisa BlairSVP, Chief HR Officer
Tax Withholding244 shares2026-08-01
82/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
71.6%
Net Margin
9.1%
Revenue CAGR
26.1%
Current Ratio
2.81x
Debt / Equity
0.63x
Return on Equity
16.3%
Earnings Summary
Insulet Corporation specializes in insulin delivery systems, notably the Omnipod 5 automated platform and the Omnipod DASH handheld device, serving patients with insulin‑dependent diabetes and chemotherapy patients through its Neulasta Onpro pods. The medical device sector is driven by aging populations and increasing diabetes prevalence, positioning Insulet within a high‑growth niche of diabetes care technology. In the last two quarters, EPS rose from $1.02 in Q4 2024 to $1.24 in Q3 2025, while revenue climbed from $597.5 M to $706.3 M, reflecting a 18% YoY revenue increase and a 21% EPS acceleration; the company consistently beat estimates in all four recent quarters, with EPS exceeding forecasts by 12% to 18% each period. Historically, Insulet has maintained double‑digit revenue growth over the past three years, with EPS growth lagging slightly but still positive; the company has frequently outperformed analyst expectations, particularly in Q4 2025 where EPS surpassed estimates by 18%. Recent news highlights a modest downgrade of the price target by Leerink Partners on Oct 9, citing a reassessment of growth prospects, and a routine earnings release for Q2 2026 on Oct 8 with no new guidance, underscoring the company’s stable reporting cadence.

EPS

EstBeatMiss
$0.81$1.05$1.29$1.53$1.77Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.59 - -
Q2'26$1.48$1.66+12.2%
Q1'26$1.19$1.42+19.3%
Q4'25$1.18$1.55+31.5%
Q3'25$1.15$1.24+8.1%
Q2'25$0.92$1.17+26.8%

Revenue

EstBeatMiss
$619M$684M$750M$815M$880MQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$850M - -
Q2'26$803M$802M-0.2%
Q1'26$730M$762M+4.3%
Q4'25$714M$784M+9.7%
Q3'25 - $706M -
Q2'25 - $649M -

Market Data

PODD Stock Snapshot

BEARISH18/100
$137.32−$0.81 (0.6%)
Market cap
9.77B
P/E ratio
26.0
Day range
$137.21 – $139.75
News sentiment
45/100 · Neutral
Analyst target
$167.17 (+21.7%)
Consensus
Hold · 35 analysts
52-week range+8.6% off low · -62.0% from high
$126.40$361.24
Price $137.32 DailyIQ Est. $172.08

PODD is on the weaker side of its setup, with little confirmation for a reversal yet. Thinner liquidity means moves can extend past what the fundamentals alone justify.

Reverse DCF

What growth is priced into PODD?

CHEAP

At today's price, Insulet Corporation needs to grow free cash flow about 13.3% a year for the next 10 years to justify its valuation at a 8.55% cost of capital. Over its actual history it has compounded free cash flow at 132.1% a year, so the market is asking for 118.8 percentage points below its own delivered rate. On that basis PODD looks priced below what its own growth record supports.

Implied FCF growth
13.3%
Historical FCF CAGR
132.1%
Growth gap
-118.8 pts
Verdict
CHEAP
Discount rate (WACC)
8.55%
Beta
0.74

Behaviour On Record

What PODD's own history says about today's numbers

Realized volatility (21d)
21.8% 8th pct
Below its peak
-60.8%
vs 200-day average
-26.8%
Up days (1y)
47%

Insulet Corporation is currently running 21.8% annualised volatility over the last 21 sessions. Measured against PODD's own 13 years of daily returns rather than a market-wide average, that is the 8th percentile — unusually subdued by its own history, against a typical reading of 36.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

PODD is trading -60.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -32.7%, and the deepest was -61.3% in 2023. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -26.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 7th percentile — a narrower gap than it typically runs. Over the past year PODD closed higher on 47% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 13 years of records, PODD finished the month higher 7 of 13 times, with a median return of +2.3% and an average of +0.4%. Its strongest month historically has been November at +10.6% on average, its weakest September at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: PODD has opened more than 2% away from the prior close in 165 of 3,267 sessions (5.1% of the time), with the largest gaps running +16.4% and -12.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, PODD moved an average of 4.9% in the session after earnings, closing higher 2 of those 3 times, with a median move of +5.3% and a largest of +6.0%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against PODD's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of PODD's sector?

Insulet Corporation sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Medical Devices industry group, PODD ranks 3rd of 15 tracked industries, improving.

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73
Industry rank
#3 of 15

Options Market

What is the options market pricing for PODD?

CallsPuts

For Insulet Corporation's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.69), with at-the-money implied volatility around 3.1%. The options market is pricing roughly a ±0.2% move by that expiry — a range of about $138.27–$138.91.

Put/call ratio (2026-10-16)
0.69
ATM implied volatility
3.1%
Total open interest
3,055
Expected move by 2026-10-16
±0.2% ($138.27–$138.91)

Analyst Rating Changes

Are analysts turning bullish or bearish on PODD?

Jefferies most recently reiterated its rating on Insulet Corporation to Buy on Oct 12, 2026 with a price target of $190 (from $275). Over the last 90 days, coverage has run 0 upgrades against 5 downgrades, a net bearish lean.

Latest action
Jefferies — Buy
90-day upgrades
0
90-day downgrades
5
Net rating momentum
-5
DateFirmActionRatingPrice target
Oct 12, 2026JefferiesMaintainedBuy$275 → $190
Oct 7, 2026BarclaysInitiatedEqual-Weight$150
Aug 6, 2026Canaccord GenuityMaintainedBuy$249 → $179
Aug 6, 2026Leerink PartnersDowngradeOutperform → Market Perform$247 → $145
Aug 6, 2026TD CowenMaintainedHold$294 → $144
Aug 6, 2026UBSMaintainedNeutral$174 → $150
Aug 6, 2026RBC CapitalMaintainedOutperform$245 → $160
Aug 6, 2026BernsteinMaintainedOutperform$200 → $175
Aug 6, 2026BenchmarkMaintainedBuy$250 → $185
Aug 6, 2026StifelMaintainedBuy$225 → $180
Aug 6, 2026Wells FargoDowngradeOverweight → Equal-Weight$255 → $144
Aug 6, 2026JP MorganDowngradeOverweight → Neutral$275 → $152

Earnings Release, Scored

What did Insulet Corporation's latest earnings release say?

Filed Aug 5, 2026 · SEC Form 8-K, Exhibit 99

New outlook issued
Tone75.3/ 100-5.1 vs prior release
Hedging words0.00per 100 words0.00 vs prior release
Tone, last 2 releasesScale 50–86

Most important lines

  1. 1

    Adjusted operating income 1 of $154.5 million, or 19.3% of revenue, up over 140 basis points compared to prior year

  2. 2

    Operating income of $129.7 million, or 16.2% of revenue, down 250 basis points over prior year

    Negative tone
  3. 3

    Revenue of $801.7 million, up 23.5%, or 22.7% in constant currency, and exceeded the high end of the Company’s guidance range of 20% - 22% at constant currency rates

Peers & ETF holders

PODD peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

45/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Jefferies analyst Matthew Taylor lowered Insulet’s (NASDAQ:PODD) price target from $275 to $190, maintaining a Buy rating. The downgrade reflects concerns about the company’s growth prospects and competitive pressures in the insulin pump market. The firm cited weaker earnings guidance and a crowded market as key factors behind the revised target. This adjustment signals a modest negative view on Insulet’s near‑term valuation. The rating change may influence investor sentiment and trading activity.
What did this article say?
Insulet Corporation (NASDAQ: PODD) announced on October 12, 2026 that its Omnipod Discover web‑based data platform would be available nationwide. The platform is designed for users of the Omnipod 5 insulin pump, providing caregivers and healthcare providers with visualized diabetes data and personalized insights. The release expands PODD’s product ecosystem beyond its existing tubeless pump hardware, offering a complementary digital tool for patients and clinicians. The move positions PODD to enhance user engagement and potentially increase pump adoption through integrated data management. No immediate financial guidance or earnings impact was disclosed.
What did this article say?
Leerink Partners revised its price target for Insulet (PODD) from $145 to $143, reflecting a modest downward adjustment. The firm maintains an overweight rating and a mean target of $177.33, indicating continued confidence in the company’s fundamentals. The change suggests a slight reassessment of growth prospects or valuation multiples, but does not signal a fundamental shift in the business outlook.
What did this article say?
Insulet (NASDAQ:PODD) released its second‑quarter 2026 financial results and held an earnings call on October 8. The company reported its earnings figures but did not provide any new guidance or material updates. No significant changes to revenue, profit margins, or strategic initiatives were disclosed. The announcement was largely a routine reporting of quarterly performance.
What did this article say?
Barclays analyst Christopher Pasquale opened coverage on Insulet (NASDAQ:PODD) with an equal‑weight rating and a $150 price target. The move signals a bullish view on the company’s prospects, suggesting confidence in its product pipeline and market positioning. The coverage initiation may influence investor sentiment and could lead to increased trading activity. No immediate earnings or operational updates were disclosed, but the rating reflects a positive outlook on future growth. The announcement positions Insulet favorably among peers in the diabetes care sector.
What did this article say?
Insulet Corporation announced that it will report its third‑quarter 2026 financial results on November 4, 2026, ahead of market opening. The company will host a conference call at 8:00 a.m. Eastern Time to discuss the results. Investors can access the call live or via replay on Insulet’s Investor Relations website. No earnings guidance or performance data were disclosed in the announcement. The update simply informs stakeholders of the upcoming earnings release date.
What did this article say?
Insulet (PODD) demonstrated robust growth and profitability metrics while maintaining a valuation considered reasonable compared to its peers. The company’s financial performance suggests a solid foundation for continued expansion. Analysts view the stock as an appealing option for investors seeking affordable growth exposure within the medical device sector.
What did this article say?
Insulet (PODD) identified emerging headwinds from new market entrants in 2027 and 2028. Analysts noted rising price pressure, with 10‑20% of the commercial user base potentially exposed to managed Medicaid or non‑preferred pricing. The company may negotiate additional rebate concessions of 5‑10% for 2027. Intellectual property moat is limited to one‑piece architecture, with two‑piece coverage expired. Oppenheimer maintained a perform rating.
What did this article say?
Insulet’s stock fell 57.2% over the past year, prompting analysts to question whether the current market price is justified by the company’s projected cash flows. The firm’s valuation hinges on its ongoing device and consumable sales, which drive revenue conversion into cash. A discounted‑cash‑flow model suggests the shares may be trading below intrinsic value, highlighting potential undervaluation amid declining share performance.
What did this article say?
Insulet (PODD) completed a refinancing that swapped $475 million of term loans for lower‑interest debt and expanded its revolving credit facility, improving its balance sheet. The move came after the stock had fallen 52 % year‑to‑date and a 58 % decline in total shareholder return, indicating waning investor enthusiasm. While the debt restructuring reduces interest expense, it does not address the broader loss of momentum or the recent index removal, leaving the upside limited.

Technical Analysis

Real-time indicators across multiple timeframes

18
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $6.56B combined position · 16 adding, 9 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell8,701,47212.35%$2.47B2026-01-29
BlackRock, Inc.▲ Buy6,690,1929.50%$1.02B2026-08-07
AQR Capital Management LLC▲ Buy2,455,1353.48%$373.79M2026-08-14
Baillie Gifford & Co▲ Buy2,042,3132.90%$310.94M2026-08-06
Geode Capital Management, LLC▼ Sell2,003,8612.84%$303.97M2026-08-12
Two Sigma Investments, LP▲ Buy1,903,7342.70%$289.84M2026-08-14
Invesco Ltd.▲ Buy1,694,6512.41%$258.01M2026-08-14
Morgan Stanley▲ Buy1,479,0502.10%$225.19M2026-08-13
Norges Bank▼ Sell1,047,9861.49%$159.56M2026-08-12
FMR LLC (Fidelity)▼ Sell964,2971.37%$146.81M2026-08-13
Millennium Management LLC▲ Buy865,3871.23%$131.76M2026-08-14
Goldman Sachs Group Inc▼ Sell818,2651.16%$124.58M2026-08-14
Citadel Advisors LLC▲ Buy796,7461.13%$121.30M2026-09-02
Northern Trust Corp▼ Sell649,9080.92%$98.95M2026-08-13
JPMorgan Chase & Co▲ Buy595,1230.84%$94.39M2026-08-12
Man Group plc▼ Sell517,2170.73%$78.75M2026-08-14
D. E. Shaw & Co., Inc.▲ Buy426,5200.61%$64.94M2026-08-14
Bank of America Corp▲ Buy426,4090.61%$64.92M2026-08-14
Squarepoint Ops LLC▲ Buy267,6420.38%$40.75M2026-08-14
Artisan Partners Limited Partnership▼ Sell260,2450.37%$39.62M2026-08-13
Renaissance Technologies LLC▼ Sell202,0830.29%$30.77M2026-08-13
Janus Henderson Group plc▲ Buy144,8180.21%$30.39M2026-05-18
Capital World Investors▲ Buy172,7120.25%$26.30M2026-08-12
Citigroup Inc▲ Buy158,9030.23%$24.19M2026-08-03
Bridgewater Associates, LP▲ Buy156,4130.22%$23.81M2026-08-14
Q2 2026 flow:5.56M sh bought ($848.77M)3.99M sh sold ($607.15M)net +1.57M sh (+$241.62M)
Congressional Trading Activity
9 disclosed trades · ~$1.20M est. traded value · 1 buys, 8 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-09-182026-10-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-08-182026-09-10
Tina SmithSenateMN▼ Sell$100K - $250K2026-05-072026-05-10
Tina SmithSenateMN▼ Sell$100K - $250K2026-04-292026-05-10
Tina SmithSenateMN▼ Sell$50K - $100K2024-04-042024-04-19
Tina SmithSenateMN▼ Sell$250K - $500K2020-03-172020-04-16
Tina SmithSenateMN▼ Sell$15K - $50K2018-08-302018-09-19
Tina SmithSenateMN▼ Sell$100K - $250K2018-06-012018-06-11
Tina SmithSenateMN▼ Sell$100K - $250K2018-03-022018-03-06